Michael G Katz1, Yoav Hadas2, Rasheed A Bailey3, Shahood Fazal3, Adam Vincek2, Sophia J Madjarova4, Nataly Shtraizent5, Luk H Vandenberghe6, Efrat Eliyahu7. 1. Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: Michael.Katz1@mssm.edu. 2. Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY. 3. Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY. 4. Department of Biology, Columbia University, New York, NY. 5. Grit Bio, Inc, New York, NY. 6. Grousbeck Center of Gene Therapy, Ocular Genomics Institute, Mass Eye and Ear, Boston, Mass; Department of Ophthalmology, Harvard Medical School, Boston, Mass; The Broad Institute of Harvard and MIT, Cambridge, Mass. 7. Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY; Icahn School for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY.
Abstract
OBJECTIVE: Gene therapy is a promising approach in the treatment of cardiovascular diseases. Preclinical and clinical studies have demonstrated that adeno-associated viral vectors are the most attractive vehicles for gene transfer. However, preexisting immunity, delayed gene expression, and postinfection immune response limit the success of this technology. The aim of this study was to investigate the efficacy of the first synthetic adeno-associated viral lineage clone, Anc80L65, for cardiac gene therapy. METHODS: By combining 2 different reporter approaches by fluorescence with green fluorescent protein and bioluminescence (Firefly luciferase), we compared transduction efficiency of Anc80L65 and adeno-associated virus, serotype 9 in neonatal rat cardiomyocytes ex vivo and rat hearts in vivo after intramyocardial and intracoronary administration. RESULTS: In cardiomyocytes, Anc80L65 provided a green fluorescent protein expression of 28.9% (36.4 ± 3.34 cells/field) at 24 hours and approximately 100% on day 7. In contrast, adeno-associated virus, serotype 9 green fluorescent protein provided minimal green fluorescent protein expression of 5.64% at 24 hours and 11.8% on day 7. After intramyocardial injection, vector expression peaked on day 7 with Anc80L65; however, with adeno-associated virus, serotype 9 the peak expression was during week 6. Administration of Anc80L65 demonstrated significantly more efficient expression of reporter gene than after adeno-associated virus, serotype 9 at 6 weeks (6.81 ± 0.64 log10 gc/100 ng DNA vs 6.49 ± 0.28 log10 gc/100 ng DNA, P < .05). These results were consistent with the amount of genome copy per cell observed in the heart. CONCLUSIONS: Anc80L65 vector allows fast and robust gene transduction compared with adeno-associated virus, serotype 9 vector in cardiac gene therapy. Anc80L65 did not adversely affect cardiac function and caused no inflammatory response or toxicity.
OBJECTIVE: Gene therapy is a promising approach in the treatment of cardiovascular diseases. Preclinical and clinical studies have demonstrated that adeno-associated viral vectors are the most attractive vehicles for gene transfer. However, preexisting immunity, delayed gene expression, and postinfection immune response limit the success of this technology. The aim of this study was to investigate the efficacy of the first synthetic adeno-associated viral lineage clone, Anc80L65, for cardiac gene therapy. METHODS: By combining 2 different reporter approaches by fluorescence with green fluorescent protein and bioluminescence (Firefly luciferase), we compared transduction efficiency of Anc80L65 and adeno-associated virus, serotype 9 in neonatal rat cardiomyocytes ex vivo and rat hearts in vivo after intramyocardial and intracoronary administration. RESULTS: In cardiomyocytes, Anc80L65 provided a green fluorescent protein expression of 28.9% (36.4 ± 3.34 cells/field) at 24 hours and approximately 100% on day 7. In contrast, adeno-associated virus, serotype 9 green fluorescent protein provided minimal green fluorescent protein expression of 5.64% at 24 hours and 11.8% on day 7. After intramyocardial injection, vector expression peaked on day 7 with Anc80L65; however, with adeno-associated virus, serotype 9 the peak expression was during week 6. Administration of Anc80L65 demonstrated significantly more efficient expression of reporter gene than after adeno-associated virus, serotype 9 at 6 weeks (6.81 ± 0.64 log10 gc/100 ng DNA vs 6.49 ± 0.28 log10 gc/100 ng DNA, P < .05). These results were consistent with the amount of genome copy per cell observed in the heart. CONCLUSIONS: Anc80L65 vector allows fast and robust gene transduction compared with adeno-associated virus, serotype 9 vector in cardiac gene therapy. Anc80L65 did not adversely affect cardiac function and caused no inflammatory response or toxicity.
Authors: Christina A Pacak; Cathryn S Mah; Bijoy D Thattaliyath; Thomas J Conlon; Melissa A Lewis; Denise E Cloutier; Irene Zolotukhin; Alice F Tarantal; Barry J Byrne Journal: Circ Res Date: 2006-07-27 Impact factor: 17.367
Authors: Savita Rangarajan; Liron Walsh; Will Lester; David Perry; Bella Madan; Michael Laffan; Hua Yu; Christian Vettermann; Glenn F Pierce; Wing Y Wong; K John Pasi Journal: N Engl J Med Date: 2017-12-09 Impact factor: 91.245
Authors: Livia S Carvalho; Ru Xiao; Sarah J Wassmer; Aliete Langsdorf; Eric Zinn; Simon Pacouret; Samiksha Shah; Jason I Comander; Leo A Kim; Laurence Lim; Luk H Vandenberghe Journal: Hum Gene Ther Date: 2018-03-20 Impact factor: 5.695
Authors: Katsuya Inagaki; Sally Fuess; Theresa A Storm; Gregory A Gibson; Charles F Mctiernan; Mark A Kay; Hiroyuki Nakai Journal: Mol Ther Date: 2006-05-19 Impact factor: 11.454
Authors: Lawrence T Bish; Kevin Morine; Meg M Sleeper; Julio Sanmiguel; Di Wu; Guangping Gao; James M Wilson; H Lee Sweeney Journal: Hum Gene Ther Date: 2008-12 Impact factor: 5.695
Authors: Patrick W Serruys; Marie-Claude Morice; A Pieter Kappetein; Antonio Colombo; David R Holmes; Michael J Mack; Elisabeth Ståhle; Ted E Feldman; Marcel van den Brand; Eric J Bass; Nic Van Dyck; Katrin Leadley; Keith D Dawkins; Friedrich W Mohr Journal: N Engl J Med Date: 2009-02-18 Impact factor: 91.245
Authors: Eric Zinn; Simon Pacouret; Vadim Khaychuk; Heikki T Turunen; Livia S Carvalho; Eva Andres-Mateos; Samiksha Shah; Rajani Shelke; Anna C Maurer; Eva Plovie; Ru Xiao; Luk H Vandenberghe Journal: Cell Rep Date: 2015-07-30 Impact factor: 9.423
Authors: Michael G Katz; Sarah M Gubara; Yoav Hadas; Thomas Weber; Arvind Kumar; Efrat Eliyahu; Charles R Bridges; Anthony S Fargnoli Journal: J Thorac Cardiovasc Surg Date: 2019-09-30 Impact factor: 5.209
Authors: Guangping Gao; Luk H Vandenberghe; Mauricio R Alvira; You Lu; Roberto Calcedo; Xiangyang Zhou; James M Wilson Journal: J Virol Date: 2004-06 Impact factor: 5.103